Ballicules.com

Adefovir

HEPSERA

What it isNucleotide analog inhibiting HBV polymerase; chronic hepatitis B.

Why this oneIt retains activity against lamivudine-resistant virus.

What limits itDose-dependent nephrotoxicity and a low resistance barrier mean tenofovir and entecavir have replaced it. Hepatitis can flare on stopping.

FDA label

BOXED WARNING Severe acute hepatitis exacerbations after discontinuation; nephrotoxicity with chronic use in at-risk patients; HIV resistance if unrecognized/untreated HIV; lactic acidosis and severe hepatomegaly with steatosis (nucleoside analogs).
FDA dosingPopulationStartTargetMax
Chronic hepatitis B (adequate renal function)Adults10 mg QD10 mg QD (optimal duration unknown)10 mg QD
Chronic hepatitis B (adequate renal function)Peds >=12 yr (not recommended <12 yr)10 mg QD10 mg QD10 mg QD

Renal Adults: CrCl >=50: 10 mg q24h; 30-49: 10 mg q48h; 10-29: 10 mg q72h; hemodialysis: 10 mg q7d following dialysis. No recommendation for non-HD CrCl <10 or for adolescents with renal impairment

Hepatic No adjustment needed (label: no change in dosing required in hepatic impairment)

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient prospective data (Antiretroviral Pregnancy Registry 1-800-258-4263)

Lactation Unknown if present in human milk; weigh benefits of breastfeeding vs need for drug

⚠ BOXED WARNINGS

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Adefovir ballicule

Adefovir ballicule: receptor binding, kinetics and half-life diagram

Open Adefovir in the interactive console ↗